Key Events This Week
2 Mar: Stock opens at Rs.842.65, down 0.99% amid broad market weakness
4 Mar: Mildly bearish momentum confirmed as stock dips to Rs.831.80 (-1.29%)
5 Mar: MarketsMOJO upgrades rating to Hold; stock rallies 2.27% to Rs.850.65
6 Mar: Technical momentum shifts to mildly bullish; stock closes at Rs.865.05 (+1.69%)
Monday, 2 March: Market Weakness Sets a Cautious Tone
Strides Pharma opened the week at Rs.842.65 on 2 March 2026, down 0.99% from the previous Friday’s close of Rs.851.05. This decline occurred in tandem with a broader market sell-off, as the Sensex dropped 1.41% to 35,812.02. The stock’s volume was moderate at 5,451 shares, reflecting cautious investor sentiment amid negative market momentum. The decline aligned with early signs of a shift from sideways to mildly bearish technical momentum, as confirmed by technical indicators later in the week.
Wednesday, 4 March: Mildly Bearish Momentum Confirmed
After no trading data on 3 March, Strides Pharma’s price fell further on 4 March, closing at Rs.831.80, a 1.29% drop from the previous close. This decline was sharper than the Sensex’s 1.92% fall to 35,125.64, signalling relative underperformance. Technical analysis revealed a shift to mildly bearish momentum, with key indicators such as MACD and monthly RSI turning negative. The stock traded within a volatile range, reflecting investor uncertainty amid mixed signals. Volume increased to 6,853 shares, but On-Balance Volume (OBV) showed no clear trend, indicating lack of strong conviction behind the move.
Thursday, 5 March: Upgrade to Hold Spurs Recovery
MarketsMOJO upgraded Strides Pharma’s rating from Sell to Hold on 5 March, citing improved technicals and valuation metrics. This announcement coincided with a strong price rebound, as the stock surged 2.27% to close at Rs.850.65 on heavy volume of 17,432 shares. The upgrade reflected a reassessment of the company’s fundamentals, including a robust quarterly net profit growth of 133.64% and improved return on capital employed (ROCE) of 16.05%. Despite concerns over elevated debt and promoter share pledging, the valuation appeared attractive relative to peers, supporting the more neutral rating. The technical momentum began shifting from bearish to mildly bullish, with daily moving averages turning positive.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Friday, 6 March: Technical Momentum Shifts to Mildly Bullish
On the final trading day of the week, Strides Pharma extended its gains, closing at Rs.865.05, up 1.69% from the previous day’s close. This marked the week’s high and a 1.65% gain from the Monday open. The Sensex, in contrast, declined 0.98% to 35,232.05, highlighting the stock’s relative strength. Technical indicators showed a nuanced picture: while MACD remained mildly bearish on weekly and monthly charts, daily moving averages and monthly Bollinger Bands turned bullish. The Know Sure Thing (KST) oscillator and weekly OBV remained cautious, suggesting the rally’s sustainability was not yet confirmed. Nonetheless, the MarketsMOJO Mojo Score improved to 58.0, reflecting the upgrade to Hold and a more positive technical outlook.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-02 | Rs.842.65 | -0.99% | 35,812.02 | -1.41% |
| 2026-03-04 | Rs.831.80 | -1.29% | 35,125.64 | -1.92% |
| 2026-03-05 | Rs.850.65 | +2.27% | 35,579.03 | +1.29% |
| 2026-03-06 | Rs.865.05 | +1.69% | 35,232.05 | -0.98% |
Key Takeaways
Positive Signals: Strides Pharma outperformed the Sensex by 4.65% over the week, closing at its weekly high of Rs.865.05. The MarketsMOJO upgrade to Hold reflects improved technical momentum and attractive valuation metrics, supported by strong quarterly profit growth and enhanced ROCE. Daily moving averages and monthly Bollinger Bands indicate a budding bullish trend, suggesting potential for further recovery.
Cautionary Notes: Despite recent gains, the stock’s MACD remains mildly bearish on longer timeframes, and volume-based indicators show mixed signals, indicating that the rally may lack full conviction. Elevated debt levels and promoter share pledging pose fundamental risks that could weigh on the stock if market conditions deteriorate. Investors should monitor key support levels near Rs.790 and watch for confirmation of sustained bullish momentum.
Considering Strides Pharma Science Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Conclusion
Strides Pharma Science Ltd demonstrated resilience in a challenging market week, closing with a 1.65% gain while the Sensex declined 3.00%. The stock’s technical momentum shifted from mildly bearish to mildly bullish, supported by a MarketsMOJO upgrade to Hold and improved valuation metrics. Strong recent quarterly earnings and an enhanced ROCE underpin the positive sentiment, although elevated leverage and promoter pledging remain concerns. The mixed technical signals and volume trends suggest that investors should remain cautious and watch for confirmation of sustained upward momentum before increasing exposure. Overall, Strides Pharma’s performance this week highlights a cautious recovery phase within a volatile market environment.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
